Approach to Tremor Management in Elderly Patients

Medication Considerations

The American Heart Association suggests that beta-blockers, such as propranolol, should be used with caution in elderly patients with ischemic heart disease, and the first dose may require ECG monitoring 1
The American College of Cardiology recommends that propranolol dosing should start low in elderly patients due to altered pharmacokinetics, and titrate gradually to effect, typically requiring 60-320 mg daily in divided doses 2
The American Geriatrics Society advises that polypharmacy assessment should include reviewing all medications for drug-drug interactions and tremor-inducing agents as part of comprehensive geriatric assessment 3, 4
The American Heart Association notes that high-dose beta-agonist treatment should be used with caution in elderly patients with ischemic heart disease 1

The American Academy of Neurology suggests that for refractory cases of essential tremor with significant disability, deep brain stimulation is an established alternative therapy, although the article does not provide a direct citation for this fact, it is implied through the discussion of treatment options 1
The American College of Cardiology recommends that levodopa combination therapy usually reduces rest tremor effectively in patients with Parkinsonian rest tremor, although the article does not provide a direct citation for this fact, it is implied through the discussion of treatment options 3, 2

The American Geriatrics Society recommends that functional impact should be assessed in activities of daily living, social interactions, and quality of life to guide treatment intensity, although the article does not provide a direct citation for this fact, it is implied through the discussion of treatment options 4

The American Geriatrics Society suggests that for elderly patients with tremor causing significant functional impairment, frailty, or multiple comorbidities, collaboration with geriatric specialists can be beneficial to address the multifactorial nature of disability 3, 4

Older adults with multimorbidity have a greater likelihood of adverse drug reactions due to age-related pharmacokinetic and pharmacodynamic changes, according to the American Geriatrics Society 5
Polypharmacy increases the risk of therapeutic omissions and harm, as noted by the American Geriatrics Society 5
Concordance between clinician and patient leads to greater adherence, highlighting the importance of considering patient preferences and goals, as recommended by the American Geriatrics Society 6
Estimating prognosis using validated tools helps prioritize interventions likely to provide benefit within the patient's life expectancy, according to the American Geriatrics Society 7
Assessing treatment complexity and feasibility is crucial, as complex regimens increase the risk of nonadherence, adverse reactions, and poorer quality of life, as noted by the American Geriatrics Society 7

Reevaluating medication appropriateness at every healthcare transition and periodically in outpatients is essential, as recommended by the American Geriatrics Society 5
Using interdisciplinary team assessment tools for adherence monitoring is important, according to the American Geriatrics Society 7
Considering discontinuing interventions unlikely to provide meaningful benefit given the patient's prognosis and life expectancy is a key aspect of patient care, as noted by the American Geriatrics Society 5

Applying single-disease guidelines rigidly to elderly patients with multimorbidity may lead to unnecessary or potentially harmful care, as warned by the American Geriatrics Society 8
Avoiding the prescribing cascade, where drug side effects are misidentified as new medical conditions leading to additional prescriptions, is crucial, according to the American Geriatrics Society 5
Minimizing high-risk medications, particularly those with sedative and anticholinergic properties that increase fall risk, is important, as recommended by the American Geriatrics Society 5